The 2024 San Antonio Breast Cancer Symposium featured five days of research presentations, educational sessions, and advocacy meetings. Dr. Marisa Weiss, founder and chief medical officer of Breastcancer.org, breaks down the research that will have the most immediate impact for people diagnosed with breast cancer. Listen to the episode to hear Dr. Weiss discuss: results from the PATINA study showing that adding Ibrance (chemical name: palbociclib) to first treatments for metastatic, hormone receptor-positive, HER2-positive breast cancer improved outcomes research on the benefits of risk-reducing surgery for young women with a BRCA mutation and a history of breast cancer the importance of moving away from a “one-size-fits-all” approach to treating breast cancer and personalizing treatments for each unique person Scroll down to below the “About the guest” information to read a transcript of this podcast.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related